Wegovy and Zepbound are popular prescription medications used for weight loss. These drugs can be expensive, especially for individuals without insurance coverage. To improve accessibility, manufacturers are now offering direct-to-consumer programs with discounted prices. - Novo Nordisk is reducing the price of Wegovy for patients who pay cash, aiming to reach those without insurance coverage. - The direct-to-patient program, called NovoCare Pharmacy, will offer all dose strengths of Wegovy for $499. - This move follows a similar decision by Eli Lilly to offer its weight-loss drug Zepbound at a discounted price to cash-paying customers. - The price reduction aims to make Wegovy more accessible to individuals who are uninsured or underinsured.